COVID-19 respiratory support outside the ICU's doors. An observational study for a new operative strategy.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
04
03
2021
accepted:
05
03
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
10
11
2021
Statut:
epublish
Résumé
During the first wave of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) pandemic, we faced a massive clinical and organizational challenge having to manage critically ill patients outside the Intensive Care Unit (ICU). This was due to the significant imbalance between ICU bed availability and the number of patients presenting Acute Hypoxemic Respiratory Failure caused by SARS-CoV-2-related interstitial pneumonia. We therefore needed to perform Non-Invasive Ventilation (NIV) in non-intensive wards to assist these patients and relieve pressure on the ICUs and subsequently implemented a new organizational and clinical model. This study was aimed at evaluating its effectiveness and feasibility. We recorded the anamnestic, clinical and biochemical data of patients undergoing non-invasive mechanical ventilation while hospitalized in non-intensive CoronaVirus Disease 19 (COVID-19) wards. Data were registered on admission, during anesthesiologist counseling, and when NIV was started and suspended. We retrospectively registered the available results from routine arterial blood gas and laboratory analyses for each time point. We retrospectively enrolled 231 patients. Based on our criteria, we identified 46 patients as NIV responders, representing 19.9% of the general study population and 29.3% of the patients that spent their entire hospital stay in non-ICU wards. Overall mortality was 56.2%, with no significant differences between patients in non-intensive wards (57.3%) and those later admitted to the ICU (54%) Conclusions: NIV is safe and manageable in an emergency situation and could become part of an integrated clinical and organizational model.
Sections du résumé
BACKGROUND AND AIM
During the first wave of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) pandemic, we faced a massive clinical and organizational challenge having to manage critically ill patients outside the Intensive Care Unit (ICU). This was due to the significant imbalance between ICU bed availability and the number of patients presenting Acute Hypoxemic Respiratory Failure caused by SARS-CoV-2-related interstitial pneumonia. We therefore needed to perform Non-Invasive Ventilation (NIV) in non-intensive wards to assist these patients and relieve pressure on the ICUs and subsequently implemented a new organizational and clinical model. This study was aimed at evaluating its effectiveness and feasibility.
METHODS
We recorded the anamnestic, clinical and biochemical data of patients undergoing non-invasive mechanical ventilation while hospitalized in non-intensive CoronaVirus Disease 19 (COVID-19) wards. Data were registered on admission, during anesthesiologist counseling, and when NIV was started and suspended. We retrospectively registered the available results from routine arterial blood gas and laboratory analyses for each time point.
RESULTS
We retrospectively enrolled 231 patients. Based on our criteria, we identified 46 patients as NIV responders, representing 19.9% of the general study population and 29.3% of the patients that spent their entire hospital stay in non-ICU wards. Overall mortality was 56.2%, with no significant differences between patients in non-intensive wards (57.3%) and those later admitted to the ICU (54%) Conclusions: NIV is safe and manageable in an emergency situation and could become part of an integrated clinical and organizational model.
Identifiants
pubmed: 34738575
doi: 10.23750/abm.v92i5.11417
pmc: PMC8689321
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021365Références
PLoS One. 2020 Oct 14;15(10):e0240645
pubmed: 33052968
EClinicalMedicine. 2020 Jun 18;24:100419
pubmed: 32766538
Clin Respir J. 2016 Jan;10(1):98-103
pubmed: 25043135
Crit Care. 2017 Sep 12;21(1):240
pubmed: 28899408
Lancet. 2009 Jul 18;374(9685):250-9
pubmed: 19616722
Am J Emerg Med. 2020 Oct;38(10):2160-2168
pubmed: 33046288
Respir Physiol Neurobiol. 2020 Sep;280:103489
pubmed: 32629100
Crit Care. 2020 Jun 11;24(1):333
pubmed: 32527302
Influenza Other Respir Viruses. 2019 Jul;13(4):382-390
pubmed: 30884185
J Am Coll Emerg Physicians Open. 2020 May 21;:
pubmed: 32838370
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Crit Care Med. 2020 Sep;48(9):1400-1402
pubmed: 32706555
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Intensive Crit Care Nurs. 2020 Jun;58:102859
pubmed: 32249028
Ultrasound J. 2020 Aug 17;12(1):39
pubmed: 32785855
Intensive Care Med. 2016 Jan;42(1):82-92
pubmed: 26464393
Clin Infect Dis. 2020 Jul 27;:
pubmed: 32716496
Intern Emerg Med. 2021 Aug;16(5):1183-1190
pubmed: 33222116
Crit Care Med. 2007 Jan;35(1):18-25
pubmed: 17133177
Pulmonology. 2020 Jul - Aug;26(4):213-220
pubmed: 32362507
Respiration. 2020;99(7):617-624
pubmed: 32570265
Intern Emerg Med. 2020 Aug;15(5):767-771
pubmed: 32435934
Med Intensiva (Engl Ed). 2020 Sep 6;:
pubmed: 33067029
Am J Respir Crit Care Med. 2017 Jan 1;195(1):67-77
pubmed: 27753501
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32430410
Eur Respir J. 2021 Feb 17;57(2):
pubmed: 33033151
PLoS One. 2020 Nov 12;15(11):e0239172
pubmed: 33180787
Pulmonology. 2020 Jul - Aug;26(4):186-191
pubmed: 32386886
Eur Clin Respir J. 2020 May 28;7(1):1761677
pubmed: 33224450
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Chest. 2020 Nov;158(5):1992-2002
pubmed: 32681847
Respir Care. 2016 Dec;61(12):1681-1692
pubmed: 27624632
PLoS One. 2012;7(4):e35797
pubmed: 22563403
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860265
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1198-202
pubmed: 14990393
Crit Care. 2020 Jun 12;24(1):337
pubmed: 32532318